Appropriate Oxygen Levels for Extremely Preterm Infants: a Prospective Meta-analysis (NeOProM)
Primary Purpose
Infant, Premature, Diseases, Bronchopulmonary Dysplasia, Retinopathy of Prematurity
Status
Completed
Phase
Not Applicable
Locations
Australia
Study Type
Interventional
Intervention
Higher oxygen saturation target range (91%-95%)
Lower oxygen saturation (85%-89%)
Sponsored by
About this trial
This is an interventional treatment trial for Infant, Premature, Diseases focused on measuring prospective meta-analysis, preterm infant, pulse oximetry, oxygen saturation
Eligibility Criteria
Inclusion Criteria:
- Infants < 28wks gestation
Exclusion Criteria:
- Infants > 28wks gestation
Sites / Locations
- Canberra Hospital
- Royal Prince Alfred Hospital Women and Babies
- Liverpool Hospital
- John Hunter Hospital
- Royal North Shore Hospital, NSW
- Westmead Hospital,
- Royal Brisbane Women's Hospital
- Royal Women's Hospital
- Monash Medical Centre
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
High Oxygen saturation
Lower oxygen saturation
Arm Description
Higher (SpO2 91-95%) functional oxygen saturation target range from birth, or soon thereafter, for durations as specified in each trial protocol.
Lower (SpO2 85-89%) functional oxygen saturation target range from birth, or soon thereafter, for durations as specified in each trial protocol.
Outcomes
Primary Outcome Measures
composite outcome of death or major disability by 18-24 months corrected age
Major disability is defined as any of the following:
Bayley-III Developmental Assessment cognitive score <85 and/or language score <85
Severe visual loss
Cerebral palsy with Gross Motor Function Classification System (GMFCS) level 2 or higher or Manual Ability Classification System (MACS) level 2 or higher at 18-24 months postmenstrual age
Deafness requiring hearing aids
Secondary Outcome Measures
Retinopathy of prematurity (ROP) treatment by laser photocoagulation or cryotherapy or anti-VEGF injection
measures of respiratory support
• Measures of respiratory support, including the following separate outcomes a. supplemental oxygen requirement at 36 weeks postmenstrual age, b. postmenstrual age ceased endotracheal intubation, c. postmenstrual age ceased continuous positive airway pressure (CPAP), d. postmenstrual age ceased supplemental oxygen, e. postmenstrual age ceased home oxygen (if received).
Patent ductus arteriosus diagnosed by ultrasound and receiving medical treatment
Patent ductus arteriosus receiving surgical treatment
Weight z-score based on WHO percentile charts (WHO Multicentre Growth Reference Study Group, 2006)
Weight z-score based on WHO percentile charts (WHO Multicentre Growth Reference Study Group, 2006)
Re-admissions to hospital
Cerebral palsy with GMFCS level 2 or higher or MACS level 2 or higher at 18-24 months corrected age
Severe visual impairment (cannot fixate or is legally blind:<6/60 vision , 1.3 logMAR in both eyes or equivalent as defined by trial)
deafness requiring hearing aids
Bayley-III Developmental Assessment cognitive score <85 and/or language score <85
death
Full Information
NCT ID
NCT01124331
First Posted
May 13, 2010
Last Updated
March 11, 2019
Sponsor
University of Sydney
Collaborators
University of Otago, University of Oxford, University of Pennsylvania, University of California, San Diego
1. Study Identification
Unique Protocol Identification Number
NCT01124331
Brief Title
Appropriate Oxygen Levels for Extremely Preterm Infants: a Prospective Meta-analysis
Acronym
NeOProM
Official Title
Appropriate Levels of Oxygen Saturation for Extremely Preterm Infants: Prospective Individual Patient Data Meta-analysis
Study Type
Interventional
2. Study Status
Record Verification Date
March 2019
Overall Recruitment Status
Completed
Study Start Date
March 2005 (undefined)
Primary Completion Date
August 2014 (Actual)
Study Completion Date
August 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Sydney
Collaborators
University of Otago, University of Oxford, University of Pennsylvania, University of California, San Diego
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The primary question to be addressed by this study is: compared with a functional oxygen saturation level (SpO2) of 91-95%, does targeting SpO2 85-89% in extremely preterm infants from birth or soon after, result in a difference in mortality or major disability in survivors by 2 years corrected age (defined as gestational age plus chronological age)?
Detailed Description
Oxygen has been used in the care of small and sick newborn babies for over 60 years. However, to date there has been no reliable evidence to guide clinicians regarding what is the best level to target oxygen saturation in preterm infants to balance the four competing risks of mortality, lung disease, eye damage and developmental disability.
Five high quality randomised controlled trials are now underway assessing two different levels of oxygen saturation targeting (USA - SUPPORT; Australia - BOOST II; New Zealand - BOOST NZ; UK - BOOST II UK; Canada - COT). The value of these gold-standard trials can be further enhanced when, with careful planning, they are synthesised into a prospective meta-analysis (PMA). A PMA is one where trials are identified for inclusion in the analysis before any of the individual results are known.
We have established the Neonatal Oxygenation Prospective Meta-analysis (NeOProM) Collaboration, comprising the investigators of these five trials and a methodology team. The trials are sufficiently similar with respect to design, participants and intervention and, with planning, will have enough common outcome measures to enable their results to be prospectively meta-analysed. Together they have a combined sample size of almost 5000 enrolled infants.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infant, Premature, Diseases, Bronchopulmonary Dysplasia, Retinopathy of Prematurity, Infant, Newborn, Diseases, Infant, Very Low Birth Weight
Keywords
prospective meta-analysis, preterm infant, pulse oximetry, oxygen saturation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
4965 (Actual)
8. Arms, Groups, and Interventions
Arm Title
High Oxygen saturation
Arm Type
Experimental
Arm Description
Higher (SpO2 91-95%) functional oxygen saturation target range from birth, or soon thereafter, for durations as specified in each trial protocol.
Arm Title
Lower oxygen saturation
Arm Type
Active Comparator
Arm Description
Lower (SpO2 85-89%) functional oxygen saturation target range from birth, or soon thereafter, for durations as specified in each trial protocol.
Intervention Type
Procedure
Intervention Name(s)
Higher oxygen saturation target range (91%-95%)
Intervention Description
higher (SpO2 91-95%) functional oxygen saturation target range from birth, or soon thereafter
Intervention Type
Procedure
Intervention Name(s)
Lower oxygen saturation (85%-89%)
Intervention Description
Lower (SpO2 85%-89%)functional oxygen saturation target range from birth, or soon thereafter
Primary Outcome Measure Information:
Title
composite outcome of death or major disability by 18-24 months corrected age
Description
Major disability is defined as any of the following:
Bayley-III Developmental Assessment cognitive score <85 and/or language score <85
Severe visual loss
Cerebral palsy with Gross Motor Function Classification System (GMFCS) level 2 or higher or Manual Ability Classification System (MACS) level 2 or higher at 18-24 months postmenstrual age
Deafness requiring hearing aids
Time Frame
by 18-24 months corrected age (gestational age plus chronological age)
Secondary Outcome Measure Information:
Title
Retinopathy of prematurity (ROP) treatment by laser photocoagulation or cryotherapy or anti-VEGF injection
Time Frame
at 18-24 months corrected age
Title
measures of respiratory support
Description
• Measures of respiratory support, including the following separate outcomes a. supplemental oxygen requirement at 36 weeks postmenstrual age, b. postmenstrual age ceased endotracheal intubation, c. postmenstrual age ceased continuous positive airway pressure (CPAP), d. postmenstrual age ceased supplemental oxygen, e. postmenstrual age ceased home oxygen (if received).
Time Frame
36 weeks postmenstrual age
Title
Patent ductus arteriosus diagnosed by ultrasound and receiving medical treatment
Time Frame
at 18-24 months corrected age
Title
Patent ductus arteriosus receiving surgical treatment
Time Frame
at 18-24 months corrected age
Title
Weight z-score based on WHO percentile charts (WHO Multicentre Growth Reference Study Group, 2006)
Time Frame
18-24 months corrected age
Title
Weight z-score based on WHO percentile charts (WHO Multicentre Growth Reference Study Group, 2006)
Time Frame
at 36 weeks' postmenstrual age and discharge home
Title
Re-admissions to hospital
Time Frame
up to 18-24 months postmenstrual age
Title
Cerebral palsy with GMFCS level 2 or higher or MACS level 2 or higher at 18-24 months corrected age
Time Frame
at 18-24 months corrected age
Title
Severe visual impairment (cannot fixate or is legally blind:<6/60 vision , 1.3 logMAR in both eyes or equivalent as defined by trial)
Time Frame
at 18-24 months corrected age
Title
deafness requiring hearing aids
Time Frame
at 18-24 months corrected age
Title
Bayley-III Developmental Assessment cognitive score <85 and/or language score <85
Time Frame
2 years corrected age
Title
death
Time Frame
at 18-24 months corrected age
Other Pre-specified Outcome Measures:
Title
Subgroup analyses will be undertaken on all pre-specified primary and secondary outcomes.
Description
Subgroups:
Gestational age
less than 26 weeks
greater than or equal to 26 weeks
Inborn or outborn
Use of any antenatal corticosteroids = yes if any of the following
incomplete, less than 24 hours before birth
complete
more than 7 days before birth
started less than 24h before birth
started 24h or more before birth
Male or female gender
Small for gestation age
birth weight below trialist defined cut-point
birth weight less than 10th percentile using WHO centile charts
Multiple or singleton birth
Mode of delivery
Vaginal if any of the following: vaginal, vaginal-cephalic, vaginal-breech
Caesarean if any of the following: caesarean, caesarean section before onset of labour, caesarean section after onset of labour, caesarean section
Time of intervention commencement
less than 6 hours after birth
6 hours or more after birth
Oximeter calibration software
original
revised
Time Frame
at 18-24 months corrected age
10. Eligibility
Sex
All
Maximum Age & Unit of Time
24 Hours
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Infants < 28wks gestation
Exclusion Criteria:
Infants > 28wks gestation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lisa Askie
Organizational Affiliation
National Health and Medical Research Council, Australia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Canberra Hospital
City
Canberra
State/Province
Australian Capital Territory
Country
Australia
Facility Name
Royal Prince Alfred Hospital Women and Babies
City
Camperdown
State/Province
New South Wales
ZIP/Postal Code
2050
Country
Australia
Facility Name
Liverpool Hospital
City
Liverpool
State/Province
New South Wales
ZIP/Postal Code
2170
Country
Australia
Facility Name
John Hunter Hospital
City
New Lambton
State/Province
New South Wales
ZIP/Postal Code
2310
Country
Australia
Facility Name
Royal North Shore Hospital, NSW
City
St Leonards
State/Province
New South Wales
Country
Australia
Facility Name
Westmead Hospital,
City
Westmead
State/Province
New South Wales
ZIP/Postal Code
2145
Country
Australia
Facility Name
Royal Brisbane Women's Hospital
City
Brisbane
State/Province
Queensland
ZIP/Postal Code
4006
Country
Australia
Facility Name
Royal Women's Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3052
Country
Australia
Facility Name
Monash Medical Centre
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3800
Country
Australia
12. IPD Sharing Statement
Citations:
PubMed Identifier
21235822
Citation
Askie LM, Brocklehurst P, Darlow BA, Finer N, Schmidt B, Tarnow-Mordi W; NeOProM Collaborative Group. NeOProM: Neonatal Oxygenation Prospective Meta-analysis Collaboration study protocol. BMC Pediatr. 2011 Jan 17;11:6. doi: 10.1186/1471-2431-11-6.
Results Reference
background
PubMed Identifier
29872859
Citation
Askie LM, Darlow BA, Finer N, Schmidt B, Stenson B, Tarnow-Mordi W, Davis PG, Carlo WA, Brocklehurst P, Davies LC, Das A, Rich W, Gantz MG, Roberts RS, Whyte RK, Costantini L, Poets C, Asztalos E, Battin M, Halliday HL, Marlow N, Tin W, King A, Juszczak E, Morley CJ, Doyle LW, Gebski V, Hunter KE, Simes RJ; Neonatal Oxygenation Prospective Meta-analysis (NeOProM) Collaboration. Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA. 2018 Jun 5;319(21):2190-2201. doi: 10.1001/jama.2018.5725. Erratum In: JAMA. 2018 Jul 17;320(3):308.
Results Reference
result
Learn more about this trial
Appropriate Oxygen Levels for Extremely Preterm Infants: a Prospective Meta-analysis
We'll reach out to this number within 24 hrs